Comparison Overview

BioLife Plasma Services

VS

The Janssen Pharmaceutical Companies of Johnson & Johnson

BioLife Plasma Services

None, None, Bannockburn , Illinois , US, None
Last Update: 2025-11-20
Between 700 and 749

Every day at BioLife, we feel good knowing that what we do helps improve the lives of patients with rare diseases. While you focus on our donors, we’ll support you. We offer a purpose you can believe in, a team you can count on, opportunities for career growth, and a comprehensive benefits program, all in a fast-paced, friendly environment.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 3,509
Subsidiaries: 0
12-month incidents
0
Known data breaches
1
Attack type number
1

The Janssen Pharmaceutical Companies of Johnson & Johnson

1000 U.S. Highway 202, Raritan, New Jersey, US
Last Update: 2025-11-20
Between 750 and 799

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,253
Subsidiaries: 11
12-month incidents
0
Known data breaches
4
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/biolifeplasmaservices.jpeg
BioLife Plasma Services
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/janssen-pharmaceutical-companies-of-johnson-and-johnson.jpeg
The Janssen Pharmaceutical Companies of Johnson & Johnson
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
BioLife Plasma Services
100%
Compliance Rate
0/4 Standards Verified
The Janssen Pharmaceutical Companies of Johnson & Johnson
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for BioLife Plasma Services in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for The Janssen Pharmaceutical Companies of Johnson & Johnson in 2025.

Incident History — BioLife Plasma Services (X = Date, Y = Severity)

BioLife Plasma Services cyber incidents detection timeline including parent company and subsidiaries

Incident History — The Janssen Pharmaceutical Companies of Johnson & Johnson (X = Date, Y = Severity)

The Janssen Pharmaceutical Companies of Johnson & Johnson cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/biolifeplasmaservices.jpeg
BioLife Plasma Services
Incidents

Date Detected: 1/2024
Type:Breach
Attack Vector: Credential Stuffing
Blog: Blog
https://images.rankiteo.com/companyimages/janssen-pharmaceutical-companies-of-johnson-and-johnson.jpeg
The Janssen Pharmaceutical Companies of Johnson & Johnson
Incidents

Date Detected: 7/2025
Type:Breach
Motivation: Financial Gain
Blog: Blog

Date Detected: 8/2024
Type:Breach
Attack Vector: Hacking
Blog: Blog

Date Detected: 6/2023
Type:Breach
Motivation: Financial Gain (Plaintiffs), Corporate Accountability, Consumer Protection
Blog: Blog

FAQ

The Janssen Pharmaceutical Companies of Johnson & Johnson company demonstrates a stronger AI Cybersecurity Score compared to BioLife Plasma Services company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

The Janssen Pharmaceutical Companies of Johnson & Johnson company has faced a higher number of disclosed cyber incidents historically compared to BioLife Plasma Services company.

In the current year, The Janssen Pharmaceutical Companies of Johnson & Johnson company has reported more cyber incidents than BioLife Plasma Services company.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson company nor BioLife Plasma Services company has reported experiencing a ransomware attack publicly.

Both The Janssen Pharmaceutical Companies of Johnson & Johnson company and BioLife Plasma Services company have disclosed experiencing at least one data breach.

Neither The Janssen Pharmaceutical Companies of Johnson & Johnson company nor BioLife Plasma Services company has reported experiencing targeted cyberattacks publicly.

Neither BioLife Plasma Services company nor The Janssen Pharmaceutical Companies of Johnson & Johnson company has reported experiencing or disclosing vulnerabilities publicly.

Neither BioLife Plasma Services nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds any compliance certifications.

Neither company holds any compliance certifications.

The Janssen Pharmaceutical Companies of Johnson & Johnson company has more subsidiaries worldwide compared to BioLife Plasma Services company.

The Janssen Pharmaceutical Companies of Johnson & Johnson company employs more people globally than BioLife Plasma Services company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither BioLife Plasma Services nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds SOC 2 Type 1 certification.

Neither BioLife Plasma Services nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds SOC 2 Type 2 certification.

Neither BioLife Plasma Services nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds ISO 27001 certification.

Neither BioLife Plasma Services nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds PCI DSS certification.

Neither BioLife Plasma Services nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds HIPAA certification.

Neither BioLife Plasma Services nor The Janssen Pharmaceutical Companies of Johnson & Johnson holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

Angular is a development platform for building mobile and desktop web applications using TypeScript/JavaScript and other languages. Prior to versions 19.2.16, 20.3.14, and 21.0.1, there is a XSRF token leakage via protocol-relative URLs in angular HTTP clients. The vulnerability is a Credential Leak by App Logic that leads to the unauthorized disclosure of the Cross-Site Request Forgery (XSRF) token to an attacker-controlled domain. Angular's HttpClient has a built-in XSRF protection mechanism that works by checking if a request URL starts with a protocol (http:// or https://) to determine if it is cross-origin. If the URL starts with protocol-relative URL (//), it is incorrectly treated as a same-origin request, and the XSRF token is automatically added to the X-XSRF-TOKEN header. This issue has been patched in versions 19.2.16, 20.3.14, and 21.0.1. A workaround for this issue involves avoiding using protocol-relative URLs (URLs starting with //) in HttpClient requests. All backend communication URLs should be hardcoded as relative paths (starting with a single /) or fully qualified, trusted absolute URLs.

Risk Information
cvss4
Base: 7.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:N/SC:H/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Uncontrolled Recursion vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft deep ASN.1 structures that trigger unbounded recursive parsing. This leads to a Denial-of-Service (DoS) via stack exhaustion when parsing untrusted DER inputs. This issue has been patched in version 1.3.2.

Risk Information
cvss4
Base: 8.7
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Forge (also called `node-forge`) is a native implementation of Transport Layer Security in JavaScript. An Integer Overflow vulnerability in node-forge versions 1.3.1 and below enables remote, unauthenticated attackers to craft ASN.1 structures containing OIDs with oversized arcs. These arcs may be decoded as smaller, trusted OIDs due to 32-bit bitwise truncation, enabling the bypass of downstream OID-based security decisions. This issue has been patched in version 1.3.2.

Risk Information
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. Prior to versions 7.0.13 and 8.0.2, working with large buffers in Lua scripts can lead to a stack overflow. Users of Lua rules and output scripts may be affected when working with large buffers. This includes a rule passing a large buffer to a Lua script. This issue has been patched in versions 7.0.13 and 8.0.2. A workaround for this issue involves disabling Lua rules and output scripts, or making sure limits, such as stream.depth.reassembly and HTTP response body limits (response-body-limit), are set to less than half the stack size.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H
Description

Suricata is a network IDS, IPS and NSM engine developed by the OISF (Open Information Security Foundation) and the Suricata community. In versions from 8.0.0 to before 8.0.2, a NULL dereference can occur when the entropy keyword is used in conjunction with base64_data. This issue has been patched in version 8.0.2. A workaround involves disabling rules that use entropy in conjunction with base64_data.

Risk Information
cvss3
Base: 7.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H